Appointments & reappointments of directors.
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Venus Remedies held its Board meeting on 26th May 2026 and approved Q4 and FY26 audited financial results. The company reported strong standalone net profit of Rs. 99.31 crore for FY26, up 89% from Rs. 52.55 crore in FY25. Revenue from operations grew to Rs. 768.73 crore from Rs. 644.47 crore. The Board recommended a final dividend of Rs. 10 per share (100%) subject to shareholder approval at the AGM on 20th August 2026 (record date: 7th August 2026). Regarding director appointments: Mr. Saransh Chaudhary and Dr. Gurminder Singh Bedi were reappointed as Independent Directors for 5 years. Dr. Savita Gupta and Mr. Manu Chaudhary were appointed as Additional Directors, with Dr. Gupta being a related party (related to promoter Mr. Pawan Chaudhary).
The strong financial performance and dividend declaration are positive signals for shareholders. However, the appointment of two promoter family members (Dr. Savita Gupta and Mr. Manu Chaudhary) as directors raises governance concerns as they are related to existing board members and the Managing Director.